| __timestamp | Celldex Therapeutics, Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20622000 | 15746000 |
| Thursday, January 1, 2015 | 33837000 | 13392000 |
| Friday, January 1, 2016 | 35979000 | 9290000 |
| Sunday, January 1, 2017 | 25003000 | 7672000 |
| Monday, January 1, 2018 | 19269000 | 15293000 |
| Tuesday, January 1, 2019 | 15426000 | 22648000 |
| Wednesday, January 1, 2020 | 14456000 | 21864000 |
| Friday, January 1, 2021 | 20488000 | 37318000 |
| Saturday, January 1, 2022 | 27195000 | 48130000 |
| Sunday, January 1, 2023 | 30914000 | 108146000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, Celldex Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A cost management.
From 2014 to 2023, Celldex's SG&A expenses fluctuated, peaking in 2016 with a 36% increase from 2014, before stabilizing around $20 million in recent years. In contrast, Madrigal's SG&A costs surged dramatically, especially between 2021 and 2023, where they more than doubled, reaching over $108 million.
This stark difference highlights Madrigal's aggressive investment in administrative functions, possibly reflecting strategic expansions or increased operational activities. Meanwhile, Celldex's steadier approach suggests a focus on maintaining operational efficiency. As these companies continue to evolve, their SG&A strategies will be pivotal in shaping their financial health and competitive edge.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
Bausch Health Companies Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
MannKind Corporation and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Travere Therapeutics, Inc. and Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. or Evotec SE: Who Manages SG&A Costs Better?